3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Melanoma
50
Carcinoma, Non-Small-Cell Lung
12
Neoplasms
11
Neoplasm Metastasis
10
Carcinoma, Renal Cell
7
Skin Neoplasms
5
Prostatic Neoplasms
4
Ovarian Neoplasms
4
Lung Neoplasms
4
Glioblastoma
4
Diabetes Mellitus, Insulin-Dependent, 12
4
Carcinoma, Hepatocellular
4
Brain Neoplasms
4
Advanced Cancer
4
Uveal Melanoma
3
Triple Negative Breast Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Small Cell Lung Carcinoma
3
Recurrence
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Pancreatic Neoplasms
3
Multiple Myeloma
3
Lymphoma, Non-Hodgkin
3
Lymphoma
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Breast Neoplasms
3
Waldenstrom Macroglobulinemia
2
Sarcoma
2
Myeloproliferative Disorders
2
Lymphoma, Mantle-Cell
2
Interventions
Influenza Vaccines
3
SARS-CoV-2 inactivated vaccines
1
Nivolumab
1
Lenalidomide
1
Ipilimumab
1
Haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugate
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Diphtheria-Tetanus Vaccine
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Influenza, Human
×
Ipilimumab
×
Clear all
NCT05116917
2024-05-28
INFLUENCE
Herlev Hospital
Phase 2
Terminated
19 enrolled